Kevin D. Judy, MD

Kevin D. Judy, MD

Contact Dr. Judy

909 Walnut St
Philadelphia, Pennsylvania 19107

(215) 503-0524
(215) 503-9357 fax

Most Recent Peer-reviewed Publications

  1. Correction to: Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment (Journal of Neuro-Oncology, (2018), 137, 1, (171-177), 10.1007/s11060-017-2709-0)
  2. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment
  3. Patterns of Clinical Use of Stereotactic Laser Ablation: Analysis of a Multicenter Prospective Registry
  4. Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases
  5. Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas
  6. Fractionated Stereotactic Radiotherapy for Facial Nerve Schwannomas
  7. BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial
  8. Tumor volume threshold for achieving improved conformity in VMAT and Gamma Knife stereotactic radiosurgery for vestibular schwannoma
  9. Cryptococcal ventriculoperitoneal shunt infection
  10. Vorinostat as a radiosensitizer for brain metastasis: A phase i clinical trial
  11. Cancer of the Central Nervous System
  12. Predictors of hearing loss after gamma knife radiosurgery for vestibular schwannomas: Age, cochlear dose, and tumor coverage
  13. Clinically silent somatotroph adenomas are common
  14. Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging
  15. Biodistribution and dosimetry of 18F-EF5 in cancer patients with preliminary comparison of 18F-EF5 uptake versus EF5 binding in human glioblastoma
  16. Concurrent cochlear implantation with resection of skull base hemangiopericytoma following sudden deafness in an only hearing ear
  17. Poor drug distribution as a possible explanation for the results of the PRECISE trial
  18. The relationship among hypoxia, proliferation, and outcome in patients with de nouo glioblastoma: A pilot study
  19. Role of proton magnetic resonance spectroscopy in differentiating oligodendrogliomas from astrocytomas: Clinical investigative study
  20. Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status